Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Acquired by Kovack Advisors Inc.

Kovack Advisors Inc. increased its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 10.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,388 shares of the medical equipment provider’s stock after purchasing an additional 135 shares during the quarter. Kovack Advisors Inc.’s holdings in Intuitive Surgical were worth $682,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of ISRG. Mirador Capital Partners LP raised its stake in shares of Intuitive Surgical by 1.4% in the 3rd quarter. Mirador Capital Partners LP now owns 3,526 shares of the medical equipment provider’s stock valued at $1,732,000 after acquiring an additional 50 shares in the last quarter. Advisors Asset Management Inc. lifted its holdings in shares of Intuitive Surgical by 18.1% during the 1st quarter. Advisors Asset Management Inc. now owns 7,380 shares of the medical equipment provider’s stock worth $2,945,000 after acquiring an additional 1,129 shares during the period. Consolidated Planning Corp boosted its position in shares of Intuitive Surgical by 17.4% during the 3rd quarter. Consolidated Planning Corp now owns 8,099 shares of the medical equipment provider’s stock valued at $3,979,000 after acquiring an additional 1,198 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its stake in Intuitive Surgical by 617.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 89,069 shares of the medical equipment provider’s stock worth $39,622,000 after purchasing an additional 76,649 shares during the period. Finally, Brookstone Capital Management raised its holdings in shares of Intuitive Surgical by 22.4% in the 2nd quarter. Brookstone Capital Management now owns 12,530 shares of the medical equipment provider’s stock worth $5,340,000 after buying an additional 2,289 shares in the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have commented on ISRG shares. Mizuho increased their price objective on Intuitive Surgical from $440.00 to $500.00 in a research report on Thursday, October 17th. Royal Bank of Canada increased their target price on Intuitive Surgical from $525.00 to $555.00 and gave the company an “outperform” rating in a research note on Friday, October 18th. Citigroup lifted their price objective on shares of Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. Evercore ISI reissued a “cautious” rating on shares of Intuitive Surgical in a report on Friday, October 18th. Finally, Redburn Atlantic upgraded Intuitive Surgical from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $380.00 to $510.00 in a report on Friday, August 2nd. One analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $513.74.

Insider Buying and Selling

In other news, General Counsel Gary Loeb sold 300 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $475.00, for a total value of $142,500.00. Following the completion of the transaction, the general counsel now owns 1,595 shares of the company’s stock, valued at $757,625. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CEO Gary S. Guthart sold 18,151 shares of the company’s stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $511.63, for a total transaction of $9,286,596.13. Following the completion of the sale, the chief executive officer now owns 24,219 shares of the company’s stock, valued at $12,391,166.97. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel Gary Loeb sold 300 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $475.00, for a total transaction of $142,500.00. Following the transaction, the general counsel now owns 1,595 shares in the company, valued at $757,625. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 91,178 shares of company stock worth $45,897,071 in the last ninety days. 0.90% of the stock is owned by insiders.

Intuitive Surgical Trading Down 0.1 %

NASDAQ:ISRG opened at $536.69 on Thursday. The stock has a market capitalization of $191.16 billion, a P/E ratio of 86.28, a P/E/G ratio of 5.28 and a beta of 1.39. Intuitive Surgical, Inc. has a 12-month low of $287.98 and a 12-month high of $542.59. The stock has a 50-day moving average price of $495.85 and a 200 day moving average price of $455.08.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.24 by $0.32. The firm had revenue of $2.04 billion for the quarter, compared to the consensus estimate of $2.01 billion. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. On average, research analysts predict that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current fiscal year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.